07:00 , Jun 22, 2015 |  BC Week In Review  |  Company News

arGEN-X, Leo Pharma deal

arGEN-X granted Leo exclusive, worldwide rights to develop and commercialize ARGX-112 , a preclinical antibody to treat inflammation-related skin diseases. arGEN-X will receive EUR4.5 million ($5 million), which includes an upfront and pre-defined preclinical milestone...